TETRAPHASE PHARMACEUTICALS INC Restructuring and Related Cost, Expected Cost
TETRAPHASE PHARMACEUTICALS INC had Restructuring and Related Cost, Expected Cost of $2.40 million as of 2019-06-30, per its 10-Q filed 2019-08-08.
Discontinued › Notes › Restructuring and Related Activities
us-gaap:RestructuringAndRelatedCostExpectedCost1 · last filed 2020-05-07
- 2019-06-30: Restructuring and Related Cost, Expected Cost $2.40M.
- 2019-06-10: Restructuring and Related Cost, Expected Cost $2.40M.
| Period end | Restructuring and Related Cost, Expected Cost |
|---|---|
| 2019-06-30 | $2.40M 10-Q · filed 2019-08-08 |
| 2019-06-10 | $2.40M 10-Q · filed 2020-05-07 |